In this continuation of our myeloma series, we build on our prior discussion about myeloma pharmacology, this time discussing how to select the optimal regimen for treatment of our patients.

Content:

- What are the phases of multiple myeloma treatment?

- How do we determine transplant eligibility?

- What does doublet, triplet, and quadruplet therapy mean?

- What categorizes "high risk" myeloma?

- What are the current standards of care for transplant eligible patients?

- Where does "CyBorD" fit in for treatment?

- When do we consider adding daratumumab?

- Links to key trials

This episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co.

Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast

Episode 044: Myeloma Series, Pt.5 - Myeloma Treatment

The Fellow on Call: The Heme/Onc Podcast

Episode 044: Myeloma Series, Pt.5 - Myeloma Treatment